These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 6420716

  • 1. DDAVP in uremia.
    Vicente V, Alberca I, Macias JF, Lopez Borrasca A.
    Nephron; 1984; 36(2):145-6. PubMed ID: 6420716
    [No Abstract] [Full Text] [Related]

  • 2. 1-Deamino-8-D-arginine vasopressin lowers protein C activity in uremics.
    Aunsholt NA, Schmidt EB, Stoffersen E.
    Nephron; 1989; 53(1):6-8. PubMed ID: 2506477
    [Abstract] [Full Text] [Related]

  • 3. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.
    Takahashi H, Itoh M, Kobayashi I, Sakuragawa N, Shibata A.
    Tohoku J Exp Med; 1980 Oct; 132(2):133-40. PubMed ID: 6777902
    [Abstract] [Full Text] [Related]

  • 4. DDAVP, cryoprecipitate, and highly 'purified' factor VIII concentrate in uremia.
    Juhl A.
    Nephron; 1986 Oct; 43(4):305-6. PubMed ID: 3090461
    [No Abstract] [Full Text] [Related]

  • 5. Is the pro-adhesive activity of plasma von Willebrand factor counteracted by a physiological inhibitor of platelet adhesiveness?
    Porta M, Cagliero E, Kohner EM.
    Clin Sci (Lond); 1982 Feb; 62(2):239-42. PubMed ID: 6797774
    [Abstract] [Full Text] [Related]

  • 6. New ways to boost factor VIII in hemophilia: DDAVP for mild hemophilia A, von Willebrand's.
    Marwick C.
    JAMA; 1983 Jun 24; 249(24):3278-9. PubMed ID: 6406692
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of DDAVP on plasma level of factor XII.
    Nenci GG, Berrettini M, De Cunto M, Agnelli G.
    Br J Haematol; 1983 Jul 24; 54(3):489-92. PubMed ID: 6407513
    [Abstract] [Full Text] [Related]

  • 12. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus.
    Kobrinsky NL, Doyle JJ, Israels ED, Winter JS, Cheang MS, Walker RD, Bishop AJ.
    Lancet; 1985 Jun 08; 1(8441):1293-4. PubMed ID: 2860491
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
    Moffat EH, Giddings JC, Bloom AL.
    Br J Haematol; 1984 Aug 08; 57(4):651-62. PubMed ID: 6430337
    [Abstract] [Full Text] [Related]

  • 18. [The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on blood coagulation in patients with hemophilia A and in healthy men].
    Blättler W, Jacky E, Müller M, Graf M.
    Schweiz Med Wochenschr; 1979 Sep 29; 109(37):1367-8. PubMed ID: 314661
    [Abstract] [Full Text] [Related]

  • 19. High levels of circulating von Willebrand factor inhibit the release of this protein but not of plasminogen activator after DDAVP.
    Vicente V, Alberca I, Mannucci PM.
    Thromb Res; 1985 Apr 01; 38(1):101-5. PubMed ID: 3873723
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.